AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03575624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and goal-setting education, yoga
Description: This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice
Study NCT01069809 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo Injection
Study NCT01085773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise on Prescription
Description: The physical training consisted of both aerobic and strength training and took place in supervised groups.
Study NCT01085773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
Study NCT06118944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICB00 IOL
Description: Bilateral implantation of ICB00 IOL
Study NCT06118944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZCB00 IOL
Description: Bilateral implantation of ZCB00 IOL
Study NCT06118944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CNA0T0 IOL
Description: Bilateral implantation of CNA0T0 IOL
Study NCT01711476 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2
Description: In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
Study NCT01711476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Lifestyle counseling ARM 1
Description: In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
Study NCT01467089 — intervention group
Intervention type: OTHER
Intervention: Two way video assessment
Description: Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
Study NCT04487951 — intervention group
Intervention type: OTHER
Intervention: Pro BNP , Vitamin D
Description: This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.
Study NCT00711438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathlessness Intervention Service (BIS)
Description: BIS consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
Study NCT00711438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care (Standard care)
Description: Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
Study NCT00471952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxalt 10mg MLT plus Caffeine 75mg
Description: One migraine attack will be treated
Study NCT00471952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxalt 10mg MLT plus Placebo
Description: One migraine attack will be treated with Maxalt 10mg plus placebo
Study NCT00471952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Placebo
Description: One migraine attack will be treated with double placebo
Study NCT01982812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Levetiracetam
Description: liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
Study NCT01982812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard AED
Description: Active comparitor, Standard AED
Study NCT02469259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02469259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04844762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes
Description: In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
Study NCT03247218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: a low-moderate affinity, uncompetitive, NMDAR antagonist
Study NCT02524535 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic alliance
Study NCT04844762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand menthol cigarettes and substitutes
Description: In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.
Study NCT04844762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol cigarettes substitutes and menthol cigarettes
Description: In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
Study NCT00070200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00070200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00070200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00070200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00070200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT04327843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement
Description: Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
Study NCT04327843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Decanoate
Description: Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
Study NCT02972788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Proteins Derivative
Description: Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
Study NCT02972788 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
Study NCT03039803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine closure during cesarean section
Study NCT04828590 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Due to observational study
Study NCT02446145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.
Study NCT02446145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.
Study NCT03177044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural treatment
Description: 2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
Study NCT01814839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-TTRSC (revusiran)
Description: Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
Study NCT00070200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Study NCT01814839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study NCT01126294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Description: Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
Study NCT01091740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZES resolute (Endeavor Resolute)
Description: 2nd generation drug eluting stent, which is coated with zotarolimus
Study NCT01091740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EES (Xience)
Description: 2nd generation drug eluting stent, which is coated with everolimus
Study NCT02097381 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
Description: Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day).
Study NCT03311516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New functional insulin therapy
Description: the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
Study NCT01126294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Description: Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
Study NCT01126294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
Study NCT02603172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
Study NCT03311516 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: functional insulin therapy
Description: the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
Study NCT00111631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid
Study NCT00111631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed
Study NCT00111631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: As prescribed
Study NCT00111631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study NCT03809936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real tDCS
Description: Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
Study NCT03809936 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
Study NCT01391832 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
Study NCT01391832 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
Study NCT01391832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
Study NCT01391832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnet Stimulation (rTMS)
Description: For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
Study NCT02503397 — intervention group
Intervention type: DEVICE
Intervention: Auditory brainstem evoked response (ABR)
Description: Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
Study NCT04559126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-297
Description: EDP-297 Oral solution
Study NCT04559126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP-297
Study NCT01939899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Description: Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
Study NCT05674669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide (LSD) 50µg
Study NCT05674669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide (LSD) 75µg
Study NCT05674669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide (LSD) 100µg
Study NCT05674669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Lysergic Acid Diethylamide (LSD) 75µg
Study NCT05674669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide (LSD) 50µg/75µg
Study NCT03631433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: identical appearing tablets containing 600 mg of ibuprofen
Study NCT03631433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen 600 mg and acetaminophen 650 mg
Description: identical appearing tablets of the combination of ibuprofen and acetaminophen
Study NCT03847259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mechanical posture changes
Description: evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
Study NCT00351299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion titrated to effect
Study NCT00351299 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care per treating physician preference
Study NCT02436174 — intervention group
Intervention type: DEVICE
Intervention: novel device
Description: novel device being used to measure shivering
Study NCT02167958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (\< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) \* (Wt in kg) \* (0.85 if female) / (72 \* Cr)~Fludarabine dosage should be reduced per standard of care.
Study NCT02167958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide \[50mg/kg\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~.